环丝氨酸治疗结核病的临床用药指南

doi:10.3969/j.issn.1000-6621.2020.06.001

摘要/Abstract

摘要：

目前,结核病疫情仍然较为严重。环丝氨酸作为治疗耐药结核病的核心药品,缺乏具体的相关规范性指导意见。中国防痨协会临床试验专业分会、《中国防痨杂志》编辑委员会组织专家通过深入研究与讨论,制定了《环丝氨酸治疗结核病的临床用药指南》(简称“《指南》”)。本《指南》介绍了环丝氨酸的分子结构和作用机制、药效学与药代动力学、药物相互作用、耐药机制、有效性和安全性、特殊人群应用、适应证和禁忌证、剂量用法、不良反应监测与处理、临床应用注意事项等内容,以期指导医护人员规范、合理地使用环丝氨酸。

关键词: 结核, 结核, 抗多种药物性, 环丝氨酸, 治疗应用, 实践指南

Abstract:

Recently, the tuberculosis epidemic is serious. Cycloserine, as the core drug in the treatment of drug-resistant tuberculosis, lacks the relevant guidance. The Clinical Trial Branch of the Chinese Antituberculosis Association and the Editorial Board of the Chinese Journal of Antituberculosis organized relevant experts to discuss deeply and to develop this guideline. This guideline introduces the molecular structure and mechanism of action, pharmacodynamics, pharmacokinetics, drug interaction, drug resistance mechanism, efficacy and safety, usage of special population, indications and contraindications, dosage and usage, drug adverse effect and clinical attentions, so as to help medical staff to standardize and reasonably use cycloserine.

Key words: Tuberculosis, Tuberculosis, multidrug-resistant, Cycloserine, Therapeutic uses, Practice guideline

首都医科大学附属北京胸科医院中国防痨协会临床试验专业分会《中国防痨杂志》编辑委员会. 环丝氨酸治疗结核病的临床用药指南[J]. 中国防痨杂志, 2020, 42(6): 533-540. doi: 10.3969/j.issn.1000-6621.2020.06.001

Beijing Chest Hospital, Capital Medical University, Clinical Trial Branch of the Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis . Guideline for clinical application of cycloserine in the treatment of tuberculosis[J]. Chinese Journal of Antituberculosis, 2020, 42(6): 533-540. doi: 10.3969/j.issn.1000-6621.2020.06.001

图/表 2

参考文献 67

[1]	World Health Organization. Global tuberculosis report 2018. Geneva: World Health Organization, 2018.
[2]	Chahine EB, Karaoui LR, Mansour H . Bedaquiline: a novel diarylquinoline for multidrug-resistant tuberculosis. Ann Pharmacother, 2014,48(1):107-115.
[3]	Wong EB, Cohen KA, Bishai WR . Rising to the challenge: new therapies for tuberculosis. Trends Microbiol, 2013,21(9):493-501.
[4]	Palmero D, González Montaner P, Cufré M , et al. First series of patients with XDR and pre-XDR TB treated with regimens that included meropenen-clavulanate in Argentina. Arch Bronconeumol, 2015,51(10):e49-52.
[5]	Szumowski JD, Lynch JB . Profile of delamanid for the treatment of multidrug-resistant tuberculosis. Drug Des Devel Ther, 2015,9:677-682.
[6]	World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: World Health Organization, 2019.
[7]	中国防痨协会. 耐药结核病化学治疗指南(2019年). 北京: 人民卫生出版社, 2019.
[8]	Hidy PH, Hodge EB, Young VV , et al. Structure and reactions of cycloserine. J Am Chem Soc, 1955,77(8):2345-2346.
[9]	Fattorini L, Iona E, Ricci ML et al. Activity of 16 antimicrobial agents against drug-resistant strains of Mycobacterium tuberculosis. Microb Drug Resist, 1999,5(4):265-270.
[10]	World Health Organization. WHO treatment guidelines for drug-resistant tuberculosis, 2016 update. Geneva: World Health Organization, 2016.
[11]	Pinsker KL, Koerner SK . Chemotherapy of tuberculosis. Am J Hosp Pharm, 1976,33(3):275-283.
[12]	Hong W, Chen L, Xie J . Molecular basis underlying Mycobacterium tuberculosis D-cycloserine resistance. Is there a role for ubiquinone and meraquinone metabolic pathways? Expert Opin Ther Targets, 2014,18(6):691-701. doi: 10.1517/14728222.2014.902937 URL
[13]	Bruning JB, Murillo AC, Chacon O , et al. Structure of the Mycobacterium tuberculosis D-alanine:D-alanine ligase, a target of the antituberculosis drug D-cycloserine. Antimicrob Agents Chemother, 2011,55(1):291-301.
[14]	Lambert MP, Neuhaus FC . Mechanism of D-cycloserine action: alanine racemase from Escherichia coli W. J Bacteriol, 1972,110(3):978-987.
[15]	Neuhaus FC, Lynch JL . The enzymatic synthesis of D-alanyl-D-alanine. 3. On the inhibition of D-alanyl-D-alanine synthetase by the antibiotic D-cycloserine. Biochemistry, 1964,3(4):471-480.
[16]	Khosravi AD, Mirsaeidi M, Farahani A , et al. Prevalence of nontuberculous mycobacteria and high efficacy of d-cycloserine and its synergistic effect with clarithromycin against Mycobacterium fortuitum and Mycobacterium abscessus. Infect Drug Resist, 2018,11:2521-2532.
[17]	Handbook of anti-tuberculosis agents. Introduction. Tuberculosis (Edinb), 2008,88(2):85-86.
[18]	Cycloserine. Tuberculosis (Edinb), 2008,88(2):100-101.
[19]	Peloquin CA . Therapeutic drug monitoring in the treatment of tuberculosis. Drugs, 2002,62(15):2169-2183.
[20]	Chang MJ, Jin B, Chae JW , et al. Population pharmacokinetics of moxifloxacin, cycloserine, p-aminosalicylic acid and kanamycin for the treatment of multi-drug-resistant tuberculosis. Int J Antimicrob Agents, 2017,49(6):677-687.
[21]	Deshpande D, Alffenaar JC, Köser CU , et al. d-Cycloserine pharmacokinetics/pharmacodynamics, susceptibility, and dosing implications in multidrug-resistant tuberculosis: A Faustian deal. Clin Infect Dis, 2018,67 Suppl 3: S308-316. doi: 10.1093/cid/ciy624 URL
[22]	Alghamdi WA, Alsultan A, Al-Shaer MH , et al. Cycloserine population pharmacokinetics and pharmacodynamics in patients with tuberculosis. Antimicrob Agents Chemother, 2019,63(5):e00055-19.
[23]	Zhu M, Nix DE, Adam RD , et al. Pharmacokinetics of cycloserine under fasting conditions and with high-fat meal, orange juice, and antacids. Pharmacotherapy, 2001,21(8):891-897.
[24]	Gardner CA, Acharya T, Pablos-Méndez A . The global allia-nce for tuberculosis drug development accomplishments and future directions. Clin Chest Med, 2005, 26(2):341-347, vii.
[25]	Alsultan A, Peloquin CA . Therapeutic drug monitoring in the treatment of tuberculosis: an update. Drugs, 2014,74(8):839-854.
[26]	Mulubwa M, Mugabo P . Steady-state population pharmacokinetics of terizidone and its metabolite cycloserine in patients with drug-resistant tuberculosis. Br J Clin Pharmacol, 2019,85(9):1946-1956. doi: 10.1111/bcp.v85.9 URL
[27]	Zhu H, Guo SC, Liu ZQ , et al. Therapeutic drug monitoring of cycloserine and linezolid during anti-tuberculosis treatment in Beijing, China. Int J Tuberc Lung Dis, 2018,22(8):931-936.
[28]	Blumberg HM, Burman WJ, Chaisson RE , et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med, 2003,167(4):603-662. doi: 10.1164/rccm.167.4.603 URL
[29]	Conde MB, Melo FA, Marques AM , et al. III Brazilian Thoracic Association Guidelines on tuberculosis. J Bras Pneumol, 2009,35(10):1018-1048. doi: 10.1590/S1806-37132009001000011 URL
[30]	Malone RS, Fish DN, Spiegel DM , et al. The effect of hemodialysis on cycloserine, ethionamide, para-aminosalicylate, and clofazimine. Chest, 1999,116(4):984-990.
[31]	Kam KM, Yip CW . Surveillance of Mycobacterium tuberculosis susceptibility to second-line drugs in Hong Kong, 1995—2002, after the implementation of DOTS-plus. Int J Tuberc Lung Dis, 2004,8(6):760-766.
[32]	Evangelopoulos D, Prosser GA, Rodgers A , et al. Comparative fitness analysis of D-cycloserine resistant mutants reveals both fitness-neutral and high-fitness cost genotypes. Nat Commun, 2019,10(1):4177.
[33]	Nakatani Y, Opel-Reading HK, Merker M , et al. Role of alanine racemase mutations in Mycobacterium tuberculosis D-cycloserine resistance. Antimicrob Agents Chemother, 2017,61(12):e01575-17.
[34]	Desjardins CA, Cohen KA, Munsamy V , et al. Genomic and functional analyses of Mycobacterium tuberculosis strains implicate ald in D-cycloserine resistance. Nat Genet, 2016,48(5):544-551.
[35]	Chen J, Zhang S, Cui P , et al. Identification of novel mutations associated with cycloserine resistance in Mycobacterium tuberculosis. J Antimicrob Chemother, 2017,72(12):3272-3276. doi: 10.1093/jac/dkx316 URL
[36]	Epstein IG, Nair KG, Mulinos MG , et al. The rehabilitation of chronic, drug resistant cases of tuberculosis with cycloserine, and successful treatment of virgin cases. Dis Chest, 1961,40:276-283.
[37]	Tahao$\check{g}$lu K, Törün T, Sevim T , et al. The treatment of multidrug-resistant tuberculosis in Turkey. N Engl J Med, 2001,345(3):170-174. doi: 10.1056/NEJM200107193450303 URL
[38]	Escudero E, Peña JM, Alvarez-Sala R , et al. Multidrug-resistant tuberculosis without HIV infection: success with individualised therapy. Int J Tuberc Lung Dis, 2006,10(4):409-414.
[39]	Prasad R, Verma SK, Sahai S , et al. Efficacy and safety of kanamycin, ethionamide, PAS and cycloserine in multidrug-resistant pulmonary tuberculosis patients. Indian J Chest Dis Allied Sci, 2006,48(3):183-186.
[40]	World Health Organization. WHO Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis: 2011 Update. Geneva: World Health Organization, 2011.
[41]	Masjedi MR, Tabarsi P, Chitsaz E , et al. Outcome of treatment of MDR-TB patients with standardised regimens, Iran, 2002—2006. Int J Tuberc Lung Dis, 2008,12(7):750-755.
[42]	Takashima T, Danno K, Tamura Y , et al. Treatment outcome of patients with multidrug-resistant pulmonary tuberculosis during pregnancy. Kekkaku, 2006,81(6):413-418.
[43]	Wang J, Pang Y, Jing W , et al. Efficacy and safety of cycloserine-containing regimens in the treatment of multidrug-resistant tuberculosis: a nationwide retrospective cohort study in China. Infect Drug Resist, 2019,12:763-770.
[44]	李杨, 王飞, 吴琍敏 , 等. 环丝氨酸在耐多药结核病化学治疗中应用价值的探讨. 中国防痨杂志, 2018,40(2):168-172.
[45]	徐俊彦, 钟凯惠, 薛卫 , 等. 含环丝氨酸结核方案治疗耐多药肺结核病患者疗效及安全性. 中华生物医学工程杂志, 2019,25(1):108-111.
[46]	Lee SH, Seo KA, Lee YM , et al. Low serum concentrations of moxifloxacin, prothionamide, and cycloserine on sputum conversion in multi-drug resistant TB. Yonsei Med J, 2015,56(4):961-967. doi: 10.3349/ymj.2015.56.4.961 URL
[47]	Mitnick CD, Shin SS, Seung KJ , et al. Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med, 2008,359(6):563-574. doi: 10.1056/NEJMoa0800106 URL
[48]	Li Y, Wang F, Wu L , et al. Cycloserine for treatment of multidrug-resistant tuberculosis: a retrospective cohort study in China. Infect Drug Resist, 2019,12:721-731. doi: 10.2147/IDR URL
[49]	Donald PR . Cerebrospinal fluid concentrations of antituberculosis agents in adults and children. Tuberculosis (Edinb), 2010,90(5):279-292. doi: 10.1016/j.tube.2010.07.002 URL
[50]	Upton A, Woodhouse A, Vaughan R , et al. Evolution of central nervous system multidrug-resistant Mycobacterium tuberculosis and late relapse of cryptic prosthetic hip joint tuberculosis: complications during treatment of disseminated isoniazid-resistant tuberculosis in an immuno-compromised host. Clin Microbiol, 2009,47(2):507-510. doi: 10.1128/JCM.01473-08 URL
[51]	王黎霞, 成诗明, 周林 . 结核菌/艾滋病病毒双重感染防治工作技术指导手册.北京: 人民卫生出版社, 2012: 83-117.
[52]	Mulubwa M, Mugabo P . Amount of cycloserine emanating from terizidone metabolism and relationship with hepatic function in patients with drug-resistant tuberculosis. Drugs R D, 2019,19(3):289-296. doi: 10.1007/s40268-019-00281-4 URL
[53]	Tandon VR, Rani N, Roshi , et al. Cycloserine induced psychosis with hepatic dysfunction. Indian J Pharmacol, 2015,47(2):230-231. doi: 10.4103/0253-7613.153439 URL
[54]	Kim J, Park S, Jung CM , et al. A Case of Cycloserine-Induced Lichenoid Drug Eruption Supported by the Lymphocyte Transformation Test. Allergy Asthma Immunol Res, 2017,9(3):281-284. doi: 10.4168/aair.2017.9.3.281 URL
[55]	Hwang TJ, Wares DF, Jafarov A , et al. Safety of cycloserine and terizidone for the treatment of drug-resistant tuberculosis: a meta-analysis. Int J Tuberc Lung Dis, 2013,17(10):1257-1266. doi: 10.5588/ijtld.12.0863 URL
[56]	Vega P, Sweetland A, Acha J , et al. Psychiatric issues in the management of patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis, 2004,8(6):749-759.
[57]	缪昌东, 姜继军 . 环丝氨酸致精神异常一例. 中国防痨杂志, 2013,35(6):480.
[58]	王敬, 荆玮, 陈维 , 等. 含环丝氨酸方案治疗耐多药肺结核患者发生不良反应的临床分析. 中国防痨杂志, 2018,40(8):810-814.
[59]	张凤波, 刘平, 纪滨英 , 等. 环丝氨酸治疗耐多药肺结核不良反应66例临床观察//《中国防痨杂志》期刊社.《中国防痨杂志》创刊80周年纪念暨学术会议资料汇编. 贵阳:《中国防痨杂志》编辑委员会, 2014: 97.
[60]	裴洁, 银春莲, 覃伟 , 等. 联用环丝氨酸在耐多药肺结核治疗中的疗效及安全性研究. 传染病信息, 2015,28(4):237-240.
[61]	World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: World Health Organization, 2008.
[62]	Ramachandran G, Swaminathan S . Safety and tolerability profile of second-line anti-tuberculosis medications. Drug Saf, 2015,38(3):253-269. doi: 10.1007/s40264-015-0267-y URL
[63]	Hemanth Kumar AK, Kumar A, Kannan T , et al. Pharmacokinetics of second-line antituberculosis drugs in children with multidrug-resistant tuberculosis in India. Antimicrob Agents Chemother, 2018,62(5):e02410-17.
[64]	Aung KJ, Van Deun A, Declercq E , et al. Successful ‘9-month Bangladesh regimen’ for multidrug-resistant tuberculosis among over 500 consecutive patients. Int J Tuberc Lung Dis, 2014,18(10):1180-1187. doi: 10.5588/ijtld.14.0100 URL
[65]	Xu C, Pang Y, Li R , et al. Clinical outcome of multidrug-resistant tuberculosis patients receiving standardized second-line treatment regimen in China. J Infect, 2018,76(4):348-353. doi: 10.1016/j.jinf.2017.12.017 URL
[66]	World Health Organization. Management of MDR-TB: a field guide-a companion document to guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: World Health Organization, 2008: 20-37.
[67]	中华医学会结核病学分会. 中国耐多药和利福平耐药结核病治疗专家共识(2019年版). 中华结核和呼吸杂志, 2019,42(10):733-749.

推荐强度	具体描述
强推荐(1级)	明确显示干预措施利大于弊或弊大于利
弱推荐(2级)	利弊不确定或无论质量高低的证据均显示利弊相当

证据级别	定义
高质量(A)	非常确信估计的效应值接近真实的效应值:进一步研究也不可能改变该估计效应值的可信度
中等质量(B)	对估计的效应值确信程度中等:估计值有可能接近真实值,但仍存在二者不相同的可能性,进一步研究有可能改变该估计效应值的可信度
低质量(C)	对估计的效应值的确信程度有限:估计值与真实值可能大不相同。进一步研究极有可能改变该估计效应值的可信度
极低质量(D)	对估计的效应值几乎没有信心:估计值与真实值很可能完全不同。对效应值的任何估计都很不确定